Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | IGF1R | P08069 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271381 | 0.90 | SIRT6 (0.81) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL6151230 | 0.90 | SIRT6 (0.81) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL11551844 | 0.87 | POLB (0.71) | SIRT6POLBMAPTIGF1RALDH1A1 | |
| SCHEMBL7048817 | 0.85 | MAPT (0.85) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL12952781 | 0.83 | SIRT6 (0.71) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL1851861 | 0.82 | MAPT (0.89) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL378458 | 0.82 | MAPT (0.96) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL85535 | 0.82 | MEN1 (0.64) | POLBMAPTALDH1A1LMNA | |
| SCHEMBL13159166 | 0.81 | SIRT6 (0.69) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL12240580 | 0.81 | SIRT6 (0.74) | SIRT6POLBMAPTALDH1A1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| CN-108779094-B | Metalloenzyme inhibitor compounds | NQP 1598公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | SIRT6 2001/4885POLB 1777/4885MAPT 2507/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | SIRT6 2001/4885POLB 1777/4885MAPT 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.